Pre-Open Stock Movers 03/31: (SURF) (CHWY) (CASI) Higher; (DCTH) (RMO) (CLSN) Lower (more...)

March 31, 2021 9:22 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Pre-Open Stock Movers:

Delcath Systems, Inc. (NASDAQ: DCTH) 32% LOWER; announced positive top-line preliminary results from the company's Phase 3 FOCUS trial of HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) in patients with liver dominant metastatic ocular melanoma (mOM).

Romeo Power, Inc. (NYSE: RMO) 17.7% LOWER; announced its preliminary financial results for the fourth quarter and full year ended December 31, 2020.

Surface Oncology (Nasdaq: SURF) 15.6% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for one of the company’s lead therapeutic candidates, SRF617, for the treatment of patients with pancreatic cancer.
Chewy (NYSE: CHWY) 14.7% HIGHER; reported Q4 revenue of $2.04 billion versus the consensus estimate of $1.96 billion.

Greenlane Holdings, Inc. (NASDAQ: GNLN) 14.7% HIGHER; Greenlane and KushCo Holdings, Inc. (OTCQX: KSHB) today announced that they have entered into a definitive merger agreement, pursuant to which KushCo will become a wholly owned subsidiary of Greenlane.

Celsion Corporation (NASDAQ: CLSN) 14.7% LOWER; announced it has entered into definitive agreements with institutional investors for the purchase and sale of 11,538,462 shares of its common stock at a purchase price of $1.30 per share in a registered direct offering, for gross proceeds of $15 million before deducting placement agent fees and expenses. The closing of the offering is expected to occur on or about April 5, 2021, subject to the satisfaction of customary closing conditions.

9 Meters Biopharma, Inc. (NASDAQ: NMTR) 11.8% LOWER; commenced a proposed underwritten public offering of shares of its common stock.

CASI Pharma (NASDAQ: CASI) 10% HIGHER; CEO, Wei-Wu He, disclosed the purchase of 3 million shares on 03/26 at $2.05.

Lineage Cell Therapeutics Inc. (NYSE: LCTX) 8.9% HIGHER; Cantor Fitzgerald initiates coverage with an Overweight rating and a price target of $6.00.

Equillium, Inc. (Nasdaq: EQ) 7.4% HIGHER; announced favorable topline data from the Type A group of the EQUALISE study in patients with systemic lupus erythematosus (SLE). In this study, itolizumab, a monoclonal antibody selectively targeting the CD6-ALCAM pathway, was safe and well tolerated. In addition, itolizumab demonstrated a dose-dependent reduction of cell surface CD6 expression on effector T cells, a leading indicator of drug activity, consistent with its mechanism of action.

Cleveland-Cliffs (NYSE: CLF) 7.2% HIGHER; sees Q1 2021 adjusted EBITDA of approximately $500 million.

SQZ Biotechnologies (NYSE: SQZ) 4.8% HIGHER; Brookline initiates coverage with a Buy rating and a price target of $40.00.

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) 3.7% LOWER; Fourth quarter and full year 2020 total revenue of $34.5 million and $177.9 million, respectively

BlackBerry (NYSE: BB) 3.4% LOWER; reported Q4 EPS of $0.03, in-line with the analyst estimate of $0.03. Revenue for the quarter came in at $215 million versus the consensus estimate of $246.36 million.

ProQR Therapeutics N.V. (Nasdaq: PRQR) 3.2% LOWER; announced that it intends to offer and sell its ordinary shares in an underwritten public offering

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Special Reports

Related Entities

Cantor Fitzgerald, Earnings, Pre-Open Losers, Pre-Open Winners, Definitive Agreement, Pre Market Movers, FDA